EO-1001

N/A

Report date: 2023/03/30 17:16:26
NME

Base Information

Drug NameEO-1001
Drug Alias NameNT-113APL-122
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulatorsReceptor protein-tyrosine kinase erbB-2 antagonistsReceptor protein-tyrosine kinase erbB-4 antagonists
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2Receptor protein-tyrosine kinase erbB-4
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEdison Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesApollomics IncSenz Oncology
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A